Semaglutide 2.4 mg once weekly, a subcutaneously administered GLP-1 RA approved for obesity treatment in 2021, results in 1517% mean weight loss (WL) with evidence of cardioprotection
HUBERMAN: While I'm not opposed to that approach, you just want to make sure that the dosing, or I should say the relative dosing of each peptide is such that, you know, You're avoiding unnecessary increases in prolactin and cortisol, and that you're not hitting a pathway redundantly
Pharmacokinetic timing and drug overlap Understanding the pharmacokinetics of both medications helps you predict exactly what is happening in your body during the switch
Additional research is required to further assess the safety and efficacy of CT-388 in larger, more diverse populations and to determine its long-term effects on weight management, glycemic control, and cardiovascular outcomes
Clinical Timeline From STEP Trials Fatigue is the second most common non-gastrointestinal side effect of Wegovy after headache, based on data from the STEP clinical trials program